DreemBio

Dreem Bio is an early-stage biotechnology company focused on developing novel therapeutics for neurodegenerative diseases by targeting protein aggregation. The company was founded by a team of seasoned industry executives, including former leaders from Alector and Denali Therapeutics, who bring extensive experience in neuro-immunology and protein degradation. Dreem Bio utilizes a proprietary technology platform designed to identify and selectively neutralize toxic protein species associated with conditions like Alzheimer's and Parkinson's. Their approach aims to overcome the limitations of previous aggregate-targeting strategies by focusing on specific pathological conformations. The company is backed by prominent life science investors and is currently advancing its discovery-stage pipeline toward clinical development.